Dengue fever future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
No edit summary
Line 9: Line 9:
==Vaccine development==
==Vaccine development==


There is no commercially available [[vaccine]] for the dengue [[flavivirus]]. However, one of the many ongoing vaccine development programs is the Pediatric Dengue Vaccine Initiative which was set up in 2003 with the aim of accelerating the development and introduction of dengue vaccine(s) that are affordable and accessible to poor children in endemic countries.<ref>{{cite web|url=http://www.pdvi.org/|title=Pediatric Dengue Vaccine Initiative website}}</ref> Thai researchers are testing a dengue fever vaccine on 3,000-5,000 human volunteers within the next three years after having successfully conducted tests on animals and a small group of human volunteers.<ref>{{cite web|url=http://english.people.com.cn/200509/05/eng20050905_206569.html|publisher=People's Daily Online|title=Thailand to test Mahidol-developed dengue vaccine prototype|date=2005-09-05|accessdate=2006-10-08}}</ref> A number of other vaccine candidates are entering phase I or II testing.<ref>{{cite journal|title=Dengue vaccines approach the finish line|author=Edelman R|journal=Clin Infect Dis|volume=45|issue=S1|year=2007|pages=S56&ndash;S60|doi=10.1086/518148}}</ref> Sanofi reported that its vaccine was effective in a late stage program. <ref>http://www.nytimes.com/2014/04/29/business/international/sanofi-says-dengue-vaccine-succeeds-in-late-stage-trial.html?_r=0</ref>
There is no commercially available [[vaccine]] for the dengue [[flavivirus]].  A number of vaccine candidates are entering phase I or II testing.<ref>{{cite journal|title=Dengue vaccines approach the finish line|author=Edelman R|journal=Clin Infect Dis|volume=45|issue=S1|year=2007|pages=S56&ndash;S60|doi=10.1086/518148}}</ref> Sanofi reported that its vaccine was effective in a late stage program. <ref>http://www.nytimes.com/2014/04/29/business/international/sanofi-says-dengue-vaccine-succeeds-in-late-stage-trial.html?_r=0</ref>


==Inhibitors of Viral Replication==
==Inhibitors of Viral Replication==

Revision as of 16:35, 15 June 2014

Dengue Fever Microchapters

Home

Patient Info

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Dengue fever from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Dengue fever future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Dengue fever future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Dengue fever future or investigational therapies

CDC on Dengue fever future or investigational therapies

Dengue fever future or investigational therapies in the news

Blogs on Dengue fever future or investigational therapies

Directions to Hospitals Treating Dengue fever

Risk calculators and risk factors for Dengue fever future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Although there is no commercially available vaccine, there are several ongoing vaccine development programs.

Vaccine development

There is no commercially available vaccine for the dengue flavivirus. A number of vaccine candidates are entering phase I or II testing.[1] Sanofi reported that its vaccine was effective in a late stage program. [2]

Inhibitors of Viral Replication

Emerging evidence suggests that mycophenolic acid and ribivirin inhibit Dengue fever virus replication. Initial experiments showed a fivefold increase in defective viral RNA production by cells treated with each drug.[2] In vivo studies, however, have not yet been done.

References

  1. Edelman R (2007). "Dengue vaccines approach the finish line". Clin Infect Dis. 45 (S1): S56&ndash, S60. doi:10.1086/518148.
  2. http://www.nytimes.com/2014/04/29/business/international/sanofi-says-dengue-vaccine-succeeds-in-late-stage-trial.html?_r=0